On Sept. 23, 2020, Humanigen announced a strategic collaboration with Thermo Fisher Scientific to expand the manufacturing capacity for lenzilumab, that was in a Phase 3 registration study in patients with COVID-19, to support a potential Emergency Use Authorization (EUA).